News
GSK collects $320M as BioNTech, Pfizer settle mRNA patent spat with CureVac
The chapter on Pfizer and BioNTech’s mRNA patent feud with Germany’s CureVac is coming to a close, even as lawsuits over the vaccine technology continue to play out on several other fronts. | Pfizer and BioNTech have settled an mRNA patent lawsuit originally brought by CureVac in the U.
GSK Gains $370 Million Upfront, Reduced Royalties in CureVac mRNA Patent Settlement Agreement with Pfizer, BioNTech
The settlement ends US mRNA patent disputes involving COVID-19 and influenza vaccines, while positioning GSK for additional payments and global royalty benefits if BioNTech’s acquisition of CureVac closes.
American pharmaceutical giant Pfizer and German biotech firm BioNTech will pay Britain’s GSK and Germany’s CureVac US$740 ...
Pfizer and its German partner BioNTech on Friday lost their bid to overturn a ruling that their COVID-19 vaccine infringed ...
CAMBRIDGE, MA / ACCESS Newswire / August 1, 2025 / Moderna, Inc. (NASDAQ:MRNA) today announced that the UK Court of Appeal ...
Moderna is not asking that courts take the Pfizer-BioNTech COVID-19 vaccine off the market or to stop future sales, in view of the public need for the vaccines. Moderna and Pfizer's vaccines have ...
Pfizer delivered a strong Q2 earnings beat, raising FY2025 guidance and demonstrating effective cost-cutting. Learn why PFE ...
Pfizer said its full-year profit should benefit from cost cuts across its research and manufacturing operations after posting ...
Second quarter earnings season is in full swing, and the results have been largely positive so far, with more positive ...
Pfizer (NYSE:PFE) shares traded higher in the premarket on Tuesday after the New York-based pharma giant reported better-than ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback